Key result
Anysis-aspirin assay shows excellent agreement with VerifyNow, yielding ~96% sensitivity for assessing platelet inhibition.
Why the study?
Assessing platelet inhibition from aspirin is important for managing thrombotic and hemorrhagic risks, prompting the evaluation of a new assay, Anysis-aspirin, against VerifyNow-aspirin.
Does the Anysis-aspirin assay accurately assess platelet inhibition compared to the VerifyNow-aspirin assay in patients with cardiac diseases?
Population
Patients with cardiac diseases referred for the aspirin response test
Comparison
Anysis-aspirin vs VerifyNow-aspirin
Design
Comparative diagnostic assay study
Authors
Loading...
May support Anysis-aspirin evaluation as VerifyNow alternative; leaves open prospective outcome validation in cardiac patients.
Observational
Does the Anysis-aspirin assay accurately assess platelet inhibition compared to the VerifyNow-aspirin assay in patients with cardiac diseases?
Effect estimate: Cohen's kappa 0.81
Absolute Event Rate: 16.5% vs 20.9%
The Anysis-aspirin assay is a highly accurate and precise point-of-care alternative to VerifyNow for assessing platelet inhibition and aspirin resistance.
Piao et al. (2021) conducted an observational in Cardiac diseases. Anysis-aspirin assay vs. VerifyNow-aspirin assay was evaluated on Aspirin resistance rate (Cohen's kappa 0.81). The Anysis-aspirin assay demonstrated excellent agreement with VerifyNow (Cohen's kappa 0.81), yielding 96.3% sensitivity and 90.3% specificity for assessing therapeutic platelet inhibition.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: